Thromboprophylaxis of central venous lines in children with cancer: The first steps taken on the long road ahead

Acta Paediatrica, International Journal of Paediatrics

Volumn 95, Issue 9, 2006, Pages 1049-1052

  Massicotte, Patricia ^a   Mitchell, Lesley ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Central venous catheter; Malignancy; Paediatrics; Randomized clinical trial; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; THROMBIN INHIBITOR; WARFARIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETER; CHYLOTHORAX; CLINICAL TRIAL; DEATH; DRUG SAFETY; HUMAN; INCIDENCE; LUNG EMBOLISM; OUTCOME ASSESSMENT; POSTTHROMBOSIS SYNDROME; PRIORITY JOURNAL; REVIEW; SUPERIOR CAVA VEIN SYNDROME; SURVIVAL;

ANTICOAGULANTS; CATHETERIZATION, CENTRAL VENOUS; CATHETERS, INDWELLING; CHILD; HUMANS; NEOPLASMS; VENOUS THROMBOSIS; WARFARIN;

EID: 33748648841     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1080/08035250600746328     Document Type: Review

References (33)

1. Male C, Chait P, Ginsberg JS, Hanna K, Andrew M, Halton J, et al. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children: results of the PARKAA study. Prophylactic Antithrombin Replacement in Kids with ALL treated with Asparaginase. Thromb Haemost 2002;87:593-8.
2. Massicotte MP, Dix D, Monagle P, Adams M, Andrew M. Central venous catheter related thrombosis in children: analysis of the Canadian Registry of Venous Thromboembolic Complications. J Pediatr 1998;133:770-6.
3. Andrew M, David M, Adams M, Ali K, Anderson R, Barnard D, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994;83:1251-7.
4. Monagle P, Adams M, Mahoney M, Ali K, Barnard D, Bernstein M, et al. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res 2000;47:763-6.
5. Kuhle S, Koloshuk B, Marzinotto V, Bauman M, Massicotte P, Andrew M, et al. A cross-sectional study evaluating postthrombotic syndrome in children. Thromb Res 2003;111: 227-33.
6. Monreal M, Raventos A, Lerma R, Ruiz J, Lafoz E, Alastrue A, et al. Pulmonary embolism in patients with upper extremity DVT associated to venous central lines-a prospective study. Thromb Haemost 1994;72:548-50.
7. Bern MM, Lokich JJ, Wallach SR, Bothe A Jr, Benotti PN, Arkin CF, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990;112:423-8.
8. Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices-prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 1996; 75:251-3.
9. Reichardt PKA, Biakov M, Irwin D. A phase III double-blind, placebo-controlled study evaluating the efficacy and safety of daily low-molecular-weight heparin (dalteparin sodium, fragmin) in preventing catheter-related complications in cancer patients with central venous catheters. Proc Annu Am Soc Clin Onc 2002;21:1474.
10. Couban S, Goodyear M, Burnell M, Dolan S, Wasi P, Barnes D, et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 2005; 23:4063-9.
11. Verso M, Agnelli G, Bertoglio S, Di Somma FC, Paoletti F, Ageno W, et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 2005;23:4057-62.
12. Levine M. Is antithrombotic prophylaxis required in cancer patients with central venous catheters? Still an open question. J Thromb Haemost 2006;4:16-8.
13. Agnelli G, Verso M. Is antithrombotic prophylaxis required in cancer patients with central venous catheters? No. J Thromb Haemost 2006;4:14-5.
14. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126 Suppl 3:338S-400S.
15. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, et al. Development of the human coagulation system in the healthy premature infant. Blood 1988;72:1651-7.
16. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, et al. Development of the human coagulation system in the full-term infant. Blood 1987;70:165-72.
17. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood 1992;80:1998-2005.
18. Massicotte P, Adams M, Marzinotto V, Brooker LA, Andrew M. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 1996;128: 313-8.
19. Streif W, Andrew M, Marzinotto V, Massicotte P, Chan AK, Julian JA, et al. Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood 1999;94:3007-14.
20. Kuhle SMP, Dinyari M, Vegh P, Mitchell D, Marzinotto V, Chan A, et al. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. Thromb Haemost 2005;94:1164-71.
21. Massicotte P, Julian JA, Gent M, Shields K, Marzinotto V, Szechtman B, et al. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central 1052 Commentary venous line-related thrombotic complications in children: the PROTEKT trial. Thromb Res 2003;109:101-8.
22. Massicotte P, Julian JA, Gent M, Shields K, Marzinotto V, Szechtman B, et al. An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb Res 2003;109:85-92.
23. van Ommen CH, Heijboer H, Buller HR, Hirasing RA, Heijmans HS, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr 2001;139:676-81.
24. Massicotte P, Julian JA, Marzinotto V, Gent M, Shields K, Chan AK, et al. Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients. Thromb Res 2003;109: 93-9.
25. Ruud E, Holmstrøm H, de Lange C, Hogstad EM, Wesenberg F. Low-dose warfarin for the prevention of central lineassociated thromboses in children with malignancies-a randomized, controlled study. Acta Paediatr 2006;95:1053-9.
26. Young AMBG, Billingham LJ, Hughes AI, Kerr DJ, Rea D, Stanley A, et al. the WARP collaborative group UK. WARP - a multicentre prospective randomized controlled trial (RCT) of thrombosis prophylaxis with warfarin in cancer patients with central venous catheters (CVCs). Proceedings of the 2005 American Society of Clinical Oncology Annual Meeting 2005 2005;3:1843-53.
27. van Ommen CH, Ottenkamp J, Lam J, Brennickmeier M, Heijmans HSA, Buller HR, et al. The risk of postthrombotic syndrome in children with congenital heart disease. J Pediatr 2002;141:582-6.
28. Mitchell LG, Andrew M, Hanna K, Abshire T, Halton J, Anderson R, et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer 2003;97:508-16.
29. Mauz-Korholz C, Junker R, Gobel U, Nowak-Gottl U. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols). Thromb Haemost 2000;83: 840-3.
30. Nowak-Gottl U, Aschka I, Koch HG, Boos J, Dockhorn-Dworniczak B, Deufel T, et al. Resistance to activated protein C (APCR) in children with acute lymphoblastic leukaemia - the need for a prospective multicentre study. Blood Coagul Fibrinolysis 1995;6:761-4.
31. Nowak-Gottl U, Wermes C, Junker R, Koch HG, Schobess R, Fleischhack G, et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 1999; 93:1595-9.
32. Weitz JI, Bates SM. New anticoagulants. J Thromb Haemost 2005;3:1843-53.
33. Kuhle S, Lau A, Bajzar L, Vegh P, Halton J, Cherrick I, Anderson R, Desai S, McCusker P,Wu J, Abshire T, Mahoney D, Mitchell L. Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukemia treated with L-asparaginase: An in vitro study. Br J Haematol 2006 in press.